ABSTRACT
Introduction In 2023, the US reported an estimated 2,050 new penile squamous cell carcinoma (SCC) cases, with mortality rates rising to 23%. Despite therapeutic advancements, the need to identify molecular and immunotherapeutic targets, especially PD-L1 and CD8, has become increasingly evident as immunotherapy emerges as a promising treatment strategy.
Methods Tissue samples from 108 SCC patients were examined using four tissue microarrays (TMA). Alongside the assessment of histologic features and PD-L1 and CD8 expressions, a machine learning model was employed. This model, constructed in Python, leveraged various statistical tests and methodologies to discern the predictive relationships between PD-L1/CD8 expression and pathologic features, with potential implications for immunotherapy selection.
Results Histologic subtype was predominant in PD-L1 expression in tumor cells, explaining 13.5% variability, whereas combined with host response, it reached 20%. For intratumoral lymphocytes, host response stood out, explaining 11.2% of PD-L1 and 15% of CD8 variability. In peritumoral lymphocytes, host response again dominated, accounting for 21.1% of CD8 variability. These findings align with recent studies showing the importance of immune markers in predicting treatment response and prognosis.
Conclusions The study highlighted the crucial relationship between penile SCC’s pathologic features and PD-L1/CD8 expression, emphasizing their potential as both prognostic and predictive biomarkers. By integrating traditional histopathology with machine learning, we provide valuable insights for patient stratification and personalized immunotherapeutic strategies in penile SCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board at the Johns Hopkins School of Medicine (Baltimore, MD)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced is available online at https://github.com/alcideschaux/PFCK-Penis-PRY/
